From CNBC: 2024-07-30 08:04:42

Merck reported strong Q2 revenue and earnings, led by Keytruda sales. The pharmaceutical giant raised its full-year sales forecast to $63.4-$64.4 billion but lowered profit guidance due to one-time charges. Earnings per share were $2.28, revenue reached $16.11 billion, up 7%. Merck is preparing for Keytruda patent expiry in 2028, launching new drugs like Winrevair and Capvaxive.

Merck’s pharmaceutical unit revenue surged 7% in Q2, with Keytruda sales at $7.27 billion, up 16%. Gardasil sales were weaker at $2.48 billion due to lower demand in China. Winrevair generated $70 million. Januvia sales dropped 27% to $629 million due to lower demand and prices amid generic competition. Sales of Covid antiviral pill, Lagevrio, fell 46% to $110 million.



Read more at CNBC:: Merck (MRK) earnings Q2 2024